{"id":16076,"date":"2016-08-29T21:59:30","date_gmt":"2016-08-29T19:59:30","guid":{"rendered":"http:\/\/mabdesign.fr\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/"},"modified":"2016-08-29T21:59:30","modified_gmt":"2016-08-29T19:59:30","slug":"sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/","title":{"rendered":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"http:\/\/www.sanofi.com\/\">Sanofi<\/a> et <a href=\"http:\/\/www.regeneron.com\/\" target=\"_blank\" rel=\"noopener\">Regeneron Pharmaceuticals, Inc.<\/a> annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH), n\u00e9cessitant un traitement par LDL-aph\u00e9r\u00e8se hebdomadaire ou toutes les deux semaines. Cet essai a d\u00e9montr\u00e9 que chez les patients trait\u00e9s par Praluent en compl\u00e9ment\u00a0de leur traitement existant, le taux de cholest\u00e9rol LDL a diminu\u00e9 d\u2019environ 50 % par rapport au taux de d\u00e9part (contre une augmentation de 2 % pour ceux trait\u00e9s par placebo) et que Praluent a r\u00e9duit la fr\u00e9quence des s\u00e9ances de LDL-aph\u00e9r\u00e8se, de 75 % comparativement au traitement par placebo (p&lt;0,0001), crit\u00e8re primaire d\u2019efficacit\u00e9 de cette \u00e9tude. Ces r\u00e9sultats seront pr\u00e9sent\u00e9s aujourd\u2019hui dans le cadre d\u2019une s\u00e9ance sp\u00e9ciale (Hot Line session) du Congr\u00e8s de l\u2019ESC qui se tient \u00e0 Rome, Italie.<\/p>\n<p><a href=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/09\/Praluent_ESC_Press_Release_FR.pdf\" target=\"_blank\" rel=\"noopener\">Lire le communiqu\u00e9 de presse<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).<\/p>\n","protected":false},"author":1,"featured_media":8343,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,13],"tags":[],"class_list":["post-16076","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-nos-adherents"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign<\/title>\n<meta name=\"description\" content=\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-29T19:59:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"178\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC\",\"datePublished\":\"2016-08-29T19:59:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\"},\"wordCount\":209,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Nos adh\u00e9rents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\",\"name\":\"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"datePublished\":\"2016-08-29T19:59:30+00:00\",\"description\":\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"width\":178,\"height\":77,\"caption\":\"SANOFI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign","description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/","og_locale":"en_US","og_type":"article","og_title":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign","og_description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).","og_url":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/","og_site_name":"MabDesign","article_published_time":"2016-08-29T19:59:30+00:00","og_image":[{"width":178,"height":77,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","type":"image\/png"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC","datePublished":"2016-08-29T19:59:30+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/"},"wordCount":209,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","articleSection":["Actualit\u00e9s","Nos adh\u00e9rents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/","url":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/","name":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","datePublished":"2016-08-29T19:59:30+00:00","description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui la pr\u00e9sentation des r\u00e9sultats positifs d\u00e9taill\u00e9s de l\u2019essai ODYSSEY ESCAPE de phase III ayant \u00e9valu\u00e9 Praluent\u00ae (alirocumab), solution injectable, chez des patients atteints d\u2019une forme g\u00e9n\u00e9tique d\u2019hypercholest\u00e9rol\u00e9mie ou hypercholest\u00e9rol\u00e9mie familiale h\u00e9t\u00e9rozygote (HeFH).","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","width":178,"height":77,"caption":"SANOFI"},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-presentent-des-donnees-experimentales-positives-de-phase-iii-sur-praluent-alirocumab-au-congres-2016-de-lesc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"\u200bSanofi et Regeneron pr\u00e9sentent des donn\u00e9es exp\u00e9rimentales positives de Phase III sur Praluent\u00ae (alirocumab), au Congr\u00e8s 2016 de l\u2019ESC"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16076"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16076\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/8343"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}